P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES

• Wojciech Jurczak,
• Catherine C. Coombs,
• Nirav N. Shah,
• Jennifer Woyach,
• Chan Y. Cheah,
• Krish Patel,
• Kami Maddocks,
• Yucai Wang,
• Catherine E. Muehlenbein,
• Chunxiao Wang,
• Sarang Abhyankar,
• Donald E. Tsai,
• Toby A. Eyre

Affiliations

Wojciech Jurczak

1 Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

Catherine C. Coombs

2 UCI Health, Orange, United States

Nirav N. Shah

3 Medical College of Wisconsin, Milwaukee, United States

Jennifer Woyach

4 The Ohio State University Comprehensive Cancer Center, Columbus, United States

Chan Y. Cheah

5 Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia

Krish Patel

6 Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Seattle, United States

Kami Maddocks

7 The Ohio State University Comprehensive Cancer Center, Columbus, United States

Yucai Wang

8 Mayo Clinic, Division of Hematology, Rochester, United States

Catherine E. Muehlenbein

9 Loxo@Lilly, Indianapolis, United States

Chunxiao Wang

10 Eli Lilly and Company, Indianapolis, United States

Sarang Abhyankar

9 Loxo@Lilly, Indianapolis, United States

Donald E. Tsai

9 Loxo@Lilly, Indianapolis, United States

Toby A. Eyre

11 Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom